BMS-986010 is a monoclonal antibody inhibitor targeting the p19 subunit of interleukin 23 (IL-23). It reduces IL-23-induced STAT3 phosphorylation, inhibits Th17 cell differentiation, and suppresses the release of pro-inflammatory cytokines such as IL-17 and TNF-alpha. BMS-986010 shows promise in research on autoimmune diseases, including psoriasis and Crohns disease.
Target-Kategorie:
Interleukin
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
